TherapeuticsMD (TXMD) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TherapeuticsMD (TXMD) Appoints Hugh O’Dowd as CEO
November 11, 2021 6:45 AM ESTTherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company, today announced key leadership changes, including the appointment of Hugh ODowd, the Companys current President, as the Companys Chief Executive Officer and member of the board of directors. Mr. ODowd will succeed Robert G. Finizio, the Companys Co-founder and current Chief Executive Officer, effective on or before December 31, 2021. Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors.
I want to thank Rob for his strong leadership and vision over the past 13... More
